L. Derré

Discipline

Gestion et management (1) Economies et finances (1)

Type de document

Articles (30) Recensions (2)

Co-auteur

Date

Source

Mot-clé

T cells (20) Cancer (17) Cells (17) cancer (16) Patients (16) Human beings (16) Cancer (16) Patients (16) spectacle (12) Bladder (11) roman (11) Vaccination (10) Melanoma (10) Vaccination (10) Immunotherapy (10) Treatment (9) Tumors (9) Immunotherapy (9) Antigens (9) Receptors (9) Tumors (9) survie (8) Survival (8) Mice (8) Expression (8) analyse (7) Analysis (7) Number (7) protéine (6) Blood (6)

Documents écrit par L. Derré (30) | parle de L. Derré (0)

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
S. Domingos-Pereira et al. (21 déc. 2022)
Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
N. Alijaj et al. (23 févr. 2022)
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
S. Benmerzoug et al.
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.
B. Mastelic-Gavillet et al. (10 oct. 2019)
Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
S. Domingos-Pereira et al.
A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling.
K. Kuncewicz et al. (11 janv. 2019)
Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization.
P. Bohner et al. (2019)
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
S. Bobisse et al. (15 mars 2018)
Immunothérapie : une révolution dans la prise en charge du cancer de la vessie ? [Immunotherapy : a revolution in the management of urothelial bladder cancer ?]
S.M. Adam et al. (29 nov. 2017)
Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
M.F. Chevalier et al.
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
M.F. Chevalier et al. (2017)
Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion.
F. Alonso et al. (22 mars 2016)
Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.
R. Hojeij et al. (14 mars 2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
P. Baumgaertner et al. (2016)
Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.
S. Domingos-Pereira et al. (2015)
Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8(+) T cells.
L. Decrausaz et al. (2013)
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
S. Corgnac et al. (2013)
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
C. Pasero et al. (2012)
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.
P. Baumgaertner et al. (2012)
Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.
C. Pieraerts et al. (2012)
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
S. Domingos-Pereira et al. (2012)
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires.
A. Leimgruber et al. (2011)
Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses.
L. Derré et al. (2010)
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
L. Derré et al. (2010)
Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
C. Jandus et al. (2009)

next